Ovarian Reserve Following Bilateral Salpingectomy Versus Tubal Ligation During Cesarean Section

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02377128

Enrollment

Registered

2015-03-03

Start date

2015-03-31

Completion date

Unknown

Last updated

2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Reserve

Keywords

Study, focus, ovarian, reserve

Brief summary

The aforementioned study was designed to evaluate short term ovarian reserve as assessed by anti-Mullerian hormone(AMH) levels following bilateral salpingectomy versus tubal ligation, as part of cesarean sections performed in women requesting future sterilization. The investigators aim to recruit 3 groups of 15 women undergoing elective cesarean section at the investigators' institution, 2 of which request sterilization (allocated to tubal ligation or bilateral salpingectomy) and one undergoing solely cesarean section. The groups will have blood drawn for AMH prior to the procedure and at a post-operation visit 8 weeks following. This is preformed in light of validated data offering better sterilization and possible diminished future risk of ovarian cancer with salpingectomy. Also, is has been proved to be just as safe as tubal ligation. This will be performed as a randomized controlled trial.

Interventions

PROCEDUREBilateral salpingectomy

Surgical bilateral removal of fallopian tubes (not involving ovaries)

PROCEDURETubal ligation

Bilateral ligation of fallopian tubes (not involving ovaries)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Women undergoing elective cesrean section at the investigators' institution, requesting sterilization, willing to have blood withdrawn for AMH levels prior to surgery, willing to participate in 8 weeks post-operation follow up with blood withdrawn

Exclusion criteria

* Non-elective cesarean section, non willing to have blood withdrawn or participate in follow up, prior salpingectomy, prior premature ovarian failure/egg donation

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in Anti Mullerian hormone (AMH) levels ng/mL at 8 weeks	Baseline and 8 weeks following surgery	AMH levels

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026